This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BioMarin Pharmaceutical's CEO Discusses Q2 2012 Results - Earnings Call Transcript

BioMarin Pharmaceutical, Inc. (BMRN)

Q2 2012 Earnings Call

August 1, 2012 05:00 pm ET

Executives



J. J. Bienaime – Chief Executive Officer

Dan Spiegelman – Executive Vice President & Chief Financial Officer



Hank Fuchs – Executive Vice President & Chief Medical Officer



Steve Aselage – Executive Vice President & Chief Business Officer



Eugenia Shen – Investor Relations



Analysts

Mike Yee – RBC Capital Markets

Salveen Richter – Canaccord Genuity

Yaron Werber – Citi

Chris Raymond – Robert W. Baird

Matt Lowe – JP Morgan

Joseph Schwartz – Leerink Swann

Phil Nadeau – Cowen & Co.

Alethia Young – Deutsche Bank

Tim Lugo – William Blair & Company

Ian Somaiya – Piper Jaffray

Matthew Harrison – UBS

Liana Moussatos – Wedbush Morgan

Kim Lee – ThinkEquity

Brian Abrams – Wells Fargo Securities

Stephen Willey – Stifel Nicolaus



Presentation



Operator

Good day, ladies and gentlemen, and welcome to the Q2 2012 BioMarin Conference Call. My name is Chanel and I will be your operator for today. (Operator instructions.) Just as a reminder, today’s call is being recorded. I would now like to turn the call over to Ms. Eugenia Shen, Investor Relations. Please proceed.

Eugenia Shen

Thank you. On the call today is J.J. Bienaime, BioMarin’s CEO; Dan Spiegelman, CFO; Hank Fuchs, Chief Medical Officer; and Steve Aselage, Chief Business Officer.

This non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceuticals including expectations regarding BioMarin’s financial performance, commercial products, and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin’s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission in its 10(q), 10(k) and 8(k) report. And now I’d like to turn the call over to J.J., BioMarin’s CEO

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs